Clinical and social determinants of definitive surgical management in bladder cancer: A two-decade population-based analysis from the United States.

M Manas Pustake (2Texas Tech University El Paso, El Paso, United States) S Stevenson Ongsyping (1Texas Tech University Health Sciences Center, Internal Medicine, El Paso, United States) O Oboseh John Ogedegbe (Trinity Health Ann Arbor, Ypsilanti, MI) S Saif Syed (RCSI, Dublin, Ireland) M Mohammad Arfat Ganiyani (6Miami Cancer Institute, Miami, United States) A Atulya Aman Khosla Y Yashodhan Suhas Morye (Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY) R Rohan Garje (3Miami Cancer Institute, Baptist Health South Florida, Miami, United States)

Abstract

654 Background: Surgical management of bladder cancer ranges from bladder-preserving approaches to radical cystectomy. We examined factors associated with receipt of definitive bladder surgery using a large population-based cohort. Methods: We analyzed 386,304 bladder cancer patients from the SEER database (2000-2022). The primary outcome was receipt of definitive bladder surgery (excisional biopsy, partial cystectomy, or radical cystectomy) versus no surgery/local ablation only. Multivariable logistic regression was used to identify predictors adjusting for demographic, clinical, and socioeconomic factors. Results: Among 386,304 patients, 76.0% were male and 24.0% female. Median age was 72 years (IQR 63-78). The cohort was 82.6% Non-Hispanic White, 6.6% Hispanic, 5.4% Non-Hispanic Black, 4.3% Non-Hispanic Asian/Pacific Islander, and 0.4% Non-Hispanic American Indian/Alaska Native. By stage: 41.2% had carcinoma in situ, 30.3% localized disease, 5.9% regional disease, and 4.1% distant metastases. Most patients (58.2%) were married at diagnosis. Surgical Patterns: Overall, 66.6% underwent excisional biopsy (code 27), 10.8% had electrocautery/fulguration, 8.4% had no surgery, 3.4% underwent partial cystectomy (code 71), and 2.6% had radical cystectomy (code 61). Only 7.6% underwent lymph node dissection (6.8% with ≥4 nodes removed). Multivariable Analysis: In adjusted analysis (n=368,219 with complete data), factors associated with definitive surgery included: Increased likelihood: Male sex (OR 1.06, 95% CI: 1.04-1.08, p<0.001), higher income ($120,000+ vs <$40,000: OR 1.51, 95% CI: 1.39-1.64, p<0.001), extensive lymph node dissection (≥4 nodes removed: OR 20.16, 95% CI: 16.32-24.90, p<0.001). Decreased likelihood: Non-Hispanic White race (vs Hispanic: OR 0.94, 95% CI: 0.91-0.97, p<0.001), distant metastases (OR 0.37, 95% CI: 0.35-0.39, p<0.001), regional disease (OR 0.50, 95% CI: 0.48-0.54, p<0.001), unknown stage (OR 0.10, 95% CI: 0.09-0.11, p<0.001), unmarried status (single: OR 0.60, 95% CI: 0.58-0.62, p<0.001), increasing age (OR 0.999 per year, p=0.018). Conclusions: Definitive bladder surgery patterns reveal significant disparities. Male patients and those with higher socioeconomic status were more likely to receive surgical treatment, while racial minorities (specifically Hispanic patients) had higher surgery rates than Non-Hispanic Whites. Advanced disease and older age predicted non-surgical management. These findings suggest complex interactions between clinical factors and healthcare access that warrant further investigation to optimize treatment selection and address potential inequities in bladder cancer care.

Article Details

Volume / Issue Vol. 44, Issue 7_suppl
Published March 01, 2026
Pages 654-654
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (8)

M

Manas Pustake

2Texas Tech University El Paso, El Paso, United States

S

Stevenson Ongsyping

1Texas Tech University Health Sciences Center, Internal Medicine, El Paso, United States

O

Oboseh John Ogedegbe

Trinity Health Ann Arbor, Ypsilanti, MI

S

Saif Syed

RCSI, Dublin, Ireland

M

Mohammad Arfat Ganiyani

6Miami Cancer Institute, Miami, United States

A

Atulya Aman Khosla

Y

Yashodhan Suhas Morye

Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY

R

Rohan Garje

3Miami Cancer Institute, Baptist Health South Florida, Miami, United States